Uterine Leiomyosarcoma
12
3
5
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Letrozole in Uterine Leiomyosarcoma
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
Combined CRS With HIPEC in Women With Inadvertently Morcellated uLMS
Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Pazopanib for Treating Uterine Leiomyosarcoma
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma